Group items tagged

The National Institute for Health and Care Excellence (NICE) has made a new recommendation in its final guidance this week that could benefit almost 30,000 adults suffering from moderate to severe symptoms of uterine fibroids. The Department of Health and Social Care's executive non-departmental public body, NICE, has recommended linzagolix, also known as Yselty by Theramex to treat uterine fibroids. Linzagolix is recommended for use as a longer-term treatment (more than 6 months) and is not for people who need short-term treatment, for example, before planned uterine fibroid surgery. According to Jonathan Benger, NICE's Chief Medical Officer and Deputy Chief Executive, expressed his approval of the new recommendation, stating, " What makes Linzagolix particularly noteworthy is its flexibility; it can be taken either with or without hormone therapy. "This means that clinicians can now offer a more personalised approach to care, tailoring treatment to the specific needs and circumstances of each patient. "For many women, this will represent a significant improvement in managing this often challenging and distressing condition."

Myomectomy is typically a surgical procedure to remove the toxic presence of fibroids in the uterus. The risks or complications carried by a myomectomy surgery are less. Still, the observant ones faced by women are

Dr. Manavita Mahanjan has trained extensively in gyn surgeries in UK and in India. She specializes in advanced Gynecological laparoscopic procedures and Gynaecological operative services for management of complex conditions.